JNJ-4916 / J&J - LARVOL DELTA

Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination with Cetrelimab in Advanced Solid Tumors (ESMO 2025) - No abstract available

Combination therapy • Metastases • Monotherapy • Oncolytic virus • P1 data • Oncology • Solid Tumor

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | N=66 ➔ 96

Enrollment change • Metastases • Monotherapy • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Monotherapy • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Metastases • Monotherapy • New P1 trial • Oncolytic virus • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor